Klebsiella pneumoniae is a common bacteria found in the human intestines that cause serious illness if it travels to other parts of the body. Dr. Kolls and Dr. Norton have created an intranasal vaccine for Klebsiella pneumoniae that elicits protection in two ways: antibody and T-cell immunity. All current pneumonia vaccines only elicit antibodies against surface carbohydrates. This is an entirely novel vaccine platform, from the use of the adjuvant to the needle-less route of administration, and it has the potential advantage of providing much broader protection against pneumonia.